{"id":"W2591046956","doi":"10.1634/theoncologist.2016-0265","title":"Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"U.S. Food and Drug Administration; Eli Lilly and Company","keywords":"Medicine; Ramucirumab; Capecitabine; Internal medicine; Hazard ratio; Gastroenterology; Adverse effect; Clinical endpoint; Phases of clinical research; Cancer; Randomized controlled trial; Confidence interval; Oncology; Chemotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002264903,0.001696805,0.003321722,0.000417586,0.0003796546,0.001179676,0.001102529,0.001488175,0.006640745],"category_scores_gemma":[0.001840394,0.001008562,0.001287226,0.0004410555,0.001149522,0.001082282,0.0003916131,0.003321707,0.001378787],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001105277,"about_ca_system_score_gemma":0.002010578,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001074956,"about_ca_topic_score_gemma":0.002743954,"domain_scores_codex":[0.9991935,0.0004856746,0.00003962322,0.0001269129,0.00005642939,0.00009781258],"domain_scores_gemma":[0.998871,0.0002350269,0.0002538335,0.00009745602,0.0000750495,0.0004675789],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9460851,0.02401347,0.001286818,0.0005200682,0.001073536,0.00008634418,0.000080423,0.0005844395,0.006224033,0.0001174627,0.001738561,0.01818976],"study_design_scores_gemma":[0.9170974,0.07968563,0.001383175,0.00001316186,0.000222536,0.00004731539,0.00001349788,0.0004101587,0.0003350809,0.00006310587,0.0007191555,0.000009633427],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9822442,0.003694894,0.0009343976,0.0008627067,0.0006312564,0.007321375,0.001462817,0.0001790626,0.002669238],"genre_scores_gemma":[0.9803689,0.0025299,0.002518276,0.001767219,0.0005418607,0.006334945,0.002237085,0.00005168023,0.003650159],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006640745,"threshold_uncertainty_score":0.02221549,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05173664560861214,"score_gpt":0.408330866346466,"score_spread":0.3565942207378539,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}